Micafungin Pharmazac 100 Mg (Micafungin)

Micafungin blocks the enzyme β‑1,3‑D‑glucan synthase, preventing the synthesis of 1,3‑β‑D‑glucan, an essential component of the fungal cell wall. This disruption weakens the wall, causing osmotic instability and leading to fungal cell death while sparing human cells.

The appropriate dose of Micafungin Pharmazac 100 Mg is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and treatment guidelines. Dosage regimens are individualized and should follow the prescriber’s order.

Safety data for Micafungin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Micafungin Pharmazac 100 Mg product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind to membrane sterols. Echinocandins like Micafungin are generally well‑tolerated, have a low potential for drug‑drug interactions, and are effective against many Candida species, including those resistant to azoles.

Micafungin Pharmazac 100 Mg must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

The product is supplied as a sterile injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central line, typically over a 30‑ to 60‑minute infusion period, following the dosing instructions provided by the prescriber.

Serious adverse events include hepatotoxicity (significant liver enzyme elevations or liver failure), severe hypersensitivity reactions such as anaphylaxis, renal impairment, and neutropenia. Patients should be monitored regularly for liver function, renal parameters, and signs of allergic reactions during therapy.

Micafungin is contraindicated in patients with known hypersensitivity to Micafungin or any component of the formulation. Caution is advised for individuals with pre‑existing severe liver disease, uncontrolled renal impairment, or those receiving interacting medications that cannot be adjusted.